Summit Therapeutics (SMMT) Reports Q2 Loss of GBP0.07/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. TMUS
7. SPY
8. CVS
9. UNH
10. SBUX

Go back to Summit Therapeutics (SMMT) Reports Q2 Loss of GBP0.07/Share

Summit Therapeutics Reports Financial Results for the Second Quarter Ended 31 July 2015 and Operational Progress

August 27, 2015 6:59 AM EDT

OXFORD, United Kingdom, Aug. 27, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ: SMMT) (AIM: SUMM), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy ('DMD') and C. difficile infection ('CDI'), today reports its financial results for the second quarter and half-year ended 31 July 2015.

Mr Glyn Edwards, Chief Executive Officer of Summit commented: "We have made very substantial progress with our utrophin modulator programme to treat boys with DMD with the recent announcement that our lead candidate, SMT C1100, achieved... More